Naturalistic Study, Comparison of Divalproex Extended Release (ER) and Quetiapine for Adults With Acute Mania or Mixed Episodes

Overview

The primary objective of this study is to compare the efficacy and tolerability of quetiapine versus divalproex extended-release administered in a rapid oral loading fashion in the treatment of acute episodes of mania or mixed mania in bipolar disorder. Three hypotheses will be tested: Hypothesis 1: treatment ( 3 weeks) of divalproex extended-release is similar to quetiapine in the symptomatic control of mania or mixed mania Hypothesis 2: divalproex extended-release orally loaded may produce significant improvements in symptoms of mania sooner than quetiapine Hypothesis 3: divalproex extended-release may produce significantly less sedation

Full Title of Study: “A Single-Blind, Randomized, Naturalistic Pilot Study, Comparison of Divalproex ER and Quetiapine for Adults With Acute Mania or Mixed Episodes”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 2008

Detailed Description

This will be a rater-blinded, head-to-head comparison (no placebo) of divalproex ER and quetiapine in patients with symptoms of an active manic or mixed mania (symptoms of mania and depression). Forty subjects are expected to be enrolled. After screening for eligibility, eligible subjects will be randomized while hospitalized in a 1:1 ratio into 2 treatment groups: divalproex ER or quetiapine. Depakote® ER will be given orally at 30 mg/kg day initially taken at night and rounded up to nearest 500 mg dose with adjustments made through the trial as needed to obtain serum valproic acid levels of 85-125 mcg/ml. Quetiapine will be given orally at an initial dose of 200mg/day on Day 1, and titrate up to 800 mg/day. The duration of the study will be 21 days from baseline and the total number of visits including screening is five. Patients will be released from the hospital once stable and visits for the study will then take place on an outpatient basis.

Interventions

  • Drug: divalproex ER
    • Dose: 30mg per kg, rounded to nearest 500mg, dosed PO QHS. Adjustments made through trial to obtain serum valproic acid levels of 85-125 mcg/ml
  • Drug: quetiapine
    • Dose: 200mg PO QHS, titrated up to therapeutic dose of 600-800mg.

Arms, Groups and Cohorts

  • Experimental: 1 Divalproex ER
    • Divalproex ER
  • Active Comparator: 2 Quetiapine Fumarate
    • quetiapine fumarate

Clinical Trial Outcome Measures

Primary Measures

  • Primary Measure: Young Mania Rating Scale (YMRS) Primary Endpoint: Day 7
    • Time Frame: Day 7
    • Minimum: 0 Maximum: 60 Higher scores indicate worse outcome

Secondary Measures

  • Young Mania Rating Scale (YMRS) Secondary Endpoints
    • Time Frame: weekly – Day 3, 14, 21
  • Clinical Global Impression: Severity (CGI:S)
    • Time Frame: each visit
  • Clinical Global Impression: Improvement (CGI:I)
    • Time Frame: each week/visit
  • Readiness to Discharge Questionnaire (RDQ)
    • Time Frame: each week/visit in the hospital
  • Montgomery-Asberg Depression Rating Scale (MADRS)
    • Time Frame: each week/visit
  • Behavioral Activity Rating Scale (BARS)
    • Time Frame: each week/visit
  • Extrapyramidal Symptoms Rating Scale (ESRS)
    • Time Frame: each week/visit

Participating in This Clinical Trial

Inclusion Criteria

For inclusion, patients must fulfill all of the following criteria at enrollment: 1. Provide written informed consent before initiation of any study-related procedures 2. A diagnosis of Bipolar I Disorder, Most Recent Episode Manic (296.4x), or Bipolar I Disorder, Most Recent Episode Mixed (296.5x), with or without psychotic features, as defined by Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition (DSMIV) 3. Male or female, at least 18 years old 4. YMRS score equal to or greater than 17 and a CGI of 4 (moderate) or greater. 5. Female patients of childbearing potential must be using a reliable method of contraception. Reliable methods of contraception include hormonal contraceptives (e.g., oral contraceptive or long-term injectable or implantable hormonal contraceptive), double-barrier methods (e.g., condom and diaphragm, condom and foam, condom and sponge), intrauterine devices, and tubal ligation. Exclusion Criteria:

1. Known intolerance or lack of response to quetiapine fumarate or Divalproex ER as judged by the investigator. 2. Unwilling or not able to provide informed consent 3. Positive urine toxicology result on screening for cocaine, phencyclidine (PCP), opiates or amphetamines that confirms the current manic/mixed episode is better accounted by a substance intoxication or withdrawal as judged by PI. 4. History of schizophrenia or schizoaffective disorder 5. Treatment with a depot antipsychotic within 1 treatment cycle 6. Unstable medical condition including hepatic, renal, gastroenterologic, neurologic, immunologic, or hematologic diseases that is deemed by the principle investigator to likely to result in hospitalization in 6 months or death within one year 7. A female subject who is pregnant or lactating 8. Lorazepam will be provided for agitation and insomnia as needed for rescue only. Not to exceed 6 mg in the first 7 days; Not to exceed 4 mg for the next 3 days and note to exceed 2 mg/day for the remainder of the study. Those that require a greater amount of Lorazepam will be excluded. 9. Hospitalized for more than 1 week for current episode at the screen 10. Substance or alcohol dependence at enrollment and within the three months prior to enrollment (except dependence in full remission, and except for caffeine or nicotine dependence), as defined by DSM-IV criteria. 11. Known diagnosis of dementia or MCI

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of California, San Diego
  • Collaborator
    • Abbott
  • Provider of Information About this Clinical Study
    • Principal Investigator: David Feifel, Professor – University of California, San Diego
  • Overall Official(s)
    • David Feifel, MD, PhD, Principal Investigator, UCSD

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.